Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604838 · ClinicalTrials.gov registry record · Phase 1
Pivotal Study of the Al-Sense Study Protocol
A Phase 1 study of Amniotic Fluid Leakage, sponsored by Western Galilee Hospital-Nahariya.
- Completed
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
- 2
- Study locations
NCT00604838: Completed Phase 1 study of Amniotic Fluid Leakage, sponsored by Western Galilee Hospital-Nahariya.
NCT00604838 is a Phase 1 study of Amniotic Fluid Leakage that has completed, run by Western Galilee Hospital-Nahariya. The registered enrollment target is 330 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (450% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00604838, a Phase 1 study of Amniotic Fluid Leakage, has completed, sponsored by Western Galilee Hospital-Nahariya.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to demonstrate that the Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd., can distinguish between wetness sensed by pregnant women that is caused by amniotic fluid leakage and that which is caused by urinary incontinence.
Conditions Studied
Interventions
- DEVICE AL-SENSE Diagnostic Absorbent Panty liner
Study Locations (2)
Michigan
- Wayne State University / Hutzel Women's Hospital - Detroit
Other
- Western Galilee Hospital-Nahariya - Nahariya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-11 |
| Phase | Phase 1 |
What the finished NCT00604838 record still lists
NCT00604838 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (450% higher).
The record links to 1 condition, with Amniotic Fluid Leakage appearing as the primary indexed condition, and to 1 intervention - of which AL-SENSE Diagnostic Absorbent Panty liner is the first listed.
NCT00604838 reports a single indexed study location in Michigan, Other.
Frequently Asked Questions
What is clinical trial NCT00604838 about?
NCT00604838 is a clinical study titled "Pivotal Study of the Al-Sense Study Protocol". The purpose of this study is to demonstrate that the Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd., can distinguish between wetness sensed by pregnant women that is caused by amniotic fluid leakage and that which is caused by urinary incontinence.
What is the current status of trial NCT00604838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2006-05. Estimated completion is 2006-11.
What conditions does trial NCT00604838 study?
This clinical trial studies the following conditions: Amniotic Fluid Leakage.
What interventions are being tested in trial NCT00604838?
The interventions under investigation include: AL-SENSE Diagnostic Absorbent Panty liner (DEVICE).
Who is sponsoring clinical trial NCT00604838?
This trial is sponsored by Western Galilee Hospital-Nahariya, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604838 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00604838's enrollment target sits among peer trials
330 110th of 2000 higher than 1,890 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia